Benefits
Possible effects on myostatin and follistatin (two small trials)
Two small human trials in older adults have examined this. A 7-day uncontrolled proof-of-concept study in about 6 people (Gutierrez-Salmean 2014) reported a rise in the follistatin to myostatin ratio, and an 8-week randomized trial in 62 sarcopenic older men (Mafi 2019) found that myostatin fell significantly only in the groups that did resistance training, while epicatechin taken on its own did not clearly change strength. These are early, small studies, and they do not show that epicatechin adds meaningful muscle growth on top of training.
Grip and leg strength in older adults (small trials)
In the 7-day proof-of-concept study (about 6 older adults, roughly 50 mg/day) hand grip strength rose modestly. In the 8-week trial in sarcopenic older men, leg press and chest press improved most in the group that combined epicatechin with resistance training, not in the group taking epicatechin alone. Reported effects on mitochondrial biogenesis and aerobic capacity come from mouse studies and have not been confirmed in people.
Cardiovascular health and nitric oxide
Cocoa flavanols that are rich in epicatechin can raise nitric oxide production and improve endothelial function and flow-mediated dilation, and meta-analyses of cocoa flavanols report small reductions in blood pressure. Most of this evidence is for whole cocoa or mixed flavanols rather than isolated epicatechin, so it is best read as borrowed cocoa-flavanol evidence.
Mechanism of action
Myostatin suppression via Smad pathway inhibition
Epicatechin inhibits the Smad2/3 signaling pathway downstream of myostatin's ActRIIB receptor — reducing the nuclear transcription of muscle atrophy genes regulated by myostatin. Simultaneously, epicatechin upregulates follistatin (myostatin's binding antagonist) through Akt-mediated transcription. The net effect is a reduced myostatin:follistatin ratio that de-restrains muscle protein synthesis capacity, complementing direct anabolic signals from leucine/mTOR activation. eNOS activation through epicatechin's interaction with the phosphatidylinositol pathway drives cardiovascular NO benefits through a separate mechanism.
Clinical trials
Eight-week randomized, double-blind, placebo-controlled trial in 62 older men with sarcopenia (Mafi et al. 2019), with four groups: resistance training, epicatechin, resistance training plus epicatechin, and placebo. It measured myostatin, follistatin, the follistatin to myostatin ratio, and leg press and chest press strength.
Small trial in older or deconditioned adults.
Leg press and chest press strength rose most in the group that combined epicatechin with resistance training, and myostatin fell significantly only in the groups that trained; epicatechin on its own did not clearly increase strength. This is one small trial (about 15 men per group), and a separate 7-day proof-of-concept study in roughly 6 older adults reported a higher follistatin to myostatin ratio and slightly better hand grip. The muscle-building claims for isolated epicatechin supplements have run well ahead of this limited evidence.